AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B
Sino-US liver therapy developer AusperBio announced that the National Medical Products Administration (NMPA) has approved...
Sanofi to Acquire Vicebio Ltd for Up to USD 1.6 Billion, Advancing Next-Gen Vaccine Development
Vicebio Ltd has entered into an exclusive, definitive agreement to be acquired by France-based major...
AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by...
Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial
Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of...
AstraZeneca’s FLAURA2 Study Confirms Osimertinib Combo’s Survival Benefit in NSCLC
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced the final overall survival (OS) results from the Phase III...
Livzon Pharma’s LZM012 Meets Phase III Endpoint for Psoriasis Treatment
China-Based Livzon Pharmaceutical Group, a holding subsidiary of Joincare Pharmaceutical (SHA: 600380) announced that the...
Simcere Zaiming Receives FDA Clearance for Phase I Trial of FGFR2b-Targeting ADC SIM0686
China-based Simcere Pharma’s (HKG: 2096) oncology arm, Simcere Zaiming Pharmaceutical, has secured U.S. FDA clearance...
Abbott Reports Q2 2025 Sales of USD 11.14 Billion, Led by Medical Devices Growth
Abbott (NYSE: ABT) reported global sales of USD 11.14 billion for the second quarter of...
DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted...
Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution
China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of...
Bio-Thera’s BAT4406F Gets NMPA Nod for MCD and FSGS Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that its investigational drug, BAT4406F injection, has received approval...
Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Optoseeker Biotech and BioMap Collaborate to Accelerate Antibody Therapeutics Development
Optoseeker Biotech, a leader in advanced life science instrumentation, and BioMap, a pioneer in life...
Wondfo Biotech’s MSI Detection Kit Granted NMPA Marketing Clearance
Guangzhou-based Wondfo Biotech (SHE: 300482) announced that the National Medical Products Administration (NMPA) has granted...
Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent
ZhongKe Yian Medical Technology (Beijing) Co., Ltd. has secured approval from China’s National Medical Products...
NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment
China’s National Medical Products Administration (NMPA) has approved the world’s first plant-based human albumin, a...
KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection
KANTE (Shenzhen) Biotechnology Co., Ltd (“Kante-bio”) announced that it has received a Category III medical...
WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings
WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities...
Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...
CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards
China’s Center for Drug Evaluation (CDE) is currently seeking public feedback on the 96th batch...